Dimethyl fumarate modulates mtROS, an upstream pathway associated with NLRP3 activation, and it has been clinically approved for psoriasis and multiple sclerosis, in which it reduces NLRP3-mediated neuroinflammation [386, 387]. This evidence concerns the gene NLRP3 and psoriasis.